Zebrafish Chemotherapy-Induced Peripheral Neuropathy (CIPN) Models

Introduction

Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting, often irreversible adverse effect of many widely used chemotherapeutic agents, including taxanes (e.g., paclitaxel), platinum-based compounds (e.g., cisplatin, oxaliplatin), vinca alkaloids (e.g., vincristine), and proteasome inhibitors (e.g., bortezomib). CIPN is characterized by axonal degeneration, demyelination, and mitochondrial dysfunction in dorsal root ganglion (DRG) neurons and peripheral sensory nerve fibers. Patients typically present with a "glove-and-stocking" distribution of sensory symptoms—numbness, tingling, burning pain, and mechanical/thermal hypersensitivity—that can progress to motor weakness and loss of proprioception.

Current management of CIPN is limited to symptomatic relief—duloxetine is the only agent with moderate evidence for efficacy—and dose modification. No FDA-approved preventive or disease-modifying therapy exists. A central challenge in CIPN research is the lack of predictive preclinical models that recapitulate the cumulative, length-dependent axonal degeneration seen in patients.

Why Zebrafish?

• Real-Time Axon Imaging: Optical transparency of larvae enables direct, real-time imaging of peripheral axon degeneration in intact animals.
• High-Throughput Screening: Hundreds of compounds can be tested in multi-well formats at low cost.
• Conserved Neurobiology: Zebrafish peripheral neurons share molecular and functional features with mammalian DRG neurons.
• Transgenic Reporters: Transgenic reporter lines (e.g., Tg(mnx1:GFP), Tg(nbt:DsRed)) allow axon-specific visualization without invasive procedures.
• Rapid Readouts: CIPN-like phenotypes manifest within 24–72 hours of exposure.

Available Zebrafish Disease Models

We offer larval exposure models for the major CIPN-causing chemotherapeutic classes:

Phenotypic Evaluation

Key Applications

• Neurotoxicity Screening: Neurotoxicity screening of novel oncology candidates—evaluate whether lead compounds in your oncology pipeline carry CIPN risk before advancing to rodent studies.
• Neuroprotective Drug Discovery: Identify and validate compounds that prevent or reverse chemotherapy-induced axon degeneration in a high-throughput in vivo setting.
• Mechanistic Studies: Dissect molecular pathways (mitochondrial dysfunction, oxidative stress, microtubule disruption, proteasome inhibition) underlying CIPN using transgenic reporters and gene-edited lines.
• Comparative Profiling: Rank-order chemotherapeutic agents or formulation variants by their peripheral neurotoxicity potential.
• Combination Therapy Assessment: Test whether adjunctive neuroprotective agents compromise chemotherapeutic efficacy in co-treatment paradigms.

Study Examples

Zebrafish larvae (3 dpf) were exposed to paclitaxel (0.1–10 µM) for 24–48 h via bath immersion. Motor axon morphology was assessed using the Tg(mnx1:GFP) transgenic line, and touch-evoked escape response was quantified. The study demonstrated that paclitaxel causes dose-dependent motor axon shortening and reduced touch sensitivity, mimicking key features of clinical CIPN.

Fig. 1. Paclitaxel exposure causes dose-dependent motor axon truncation in Tg(mnx1:GFP) zebrafish larvae (Lisse TS, Middleton LJ, et al., 2016).

Reference

1. Lisse, T.S., Middleton, L.J., et al. Paclitaxel-induced axonal atrophy in zebrafish larvae: a model for chemotherapy-induced peripheral neuropathy. Disease Models & Mechanisms 9(8), 899–908 (2016).